Page last updated: 2024-10-21

3-methylcholanthrene and Cancer of Endometrium

3-methylcholanthrene has been researched along with Cancer of Endometrium in 3 studies

Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.
3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.

Research Excerpts

ExcerptRelevanceReference
" Dose-response studies revealed that the concentration of 3MC required to half-maximally activate transcription (EC(50)) was >100-fold higher for an ER reporter (27-57 muM) than for an AhR reporter (86-250 nM) in both MCF-7 cells and in human endometrial cancer Ishikawa cells."1.33Aryl hydrocarbon receptor-independent activation of estrogen receptor-dependent transcription by 3-methylcholanthrene. ( Shipley, JM; Waxman, DJ, 2006)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19901 (33.33)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Qu, XL1
Wang, SY1
Jia, YJ1
Guan, Y1
TAKI, I1
IIJIMA, H1
Shipley, JM1
Waxman, DJ1

Other Studies

3 other studies available for 3-methylcholanthrene and Cancer of Endometrium

ArticleYear
Aryl hydrocarbon receptor exogenous ligand 3-methylchoranthrene inhibited endometrial cancer cells proliferation.
    European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:8

    Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Cell Movement

2014
A NEW METHOD OF PRODUCING ENDOMETRIAL CANCER IN MICE.
    American journal of obstetrics and gynecology, 1963, Dec-01, Volume: 87

    Topics: Adenocarcinoma; Animals; Carcinoma, Squamous Cell; Endometrial Neoplasms; Endometrium; Female; Human

1963
Aryl hydrocarbon receptor-independent activation of estrogen receptor-dependent transcription by 3-methylcholanthrene.
    Toxicology and applied pharmacology, 2006, Jun-01, Volume: 213, Issue:2

    Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Endometrial Neoplasms

2006